Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870656 | 0.85 | ALDH1A1 (0.48) | SMN1; SMN2LMNAHTTALDH1A1FUCA1 | |
| SCHEMBL6240346 | 0.85 | ALDH1A1 (0.48) | SMN1; SMN2LMNAHTTALDH1A1FUCA1 | |
| SCHEMBL4866087 | 0.83 | EPHX2 (0.45) | ALDH1A1HTR2CNPC1RAB9A | |
| SCHEMBL6237661 | 0.83 | EPHX2 (0.45) | ALDH1A1HTR2CNPC1RAB9A | |
| SCHEMBL25568293 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAHTTALDH1A1FUCA1 | |
| SCHEMBL4870701 | 0.80 | LMNA (0.54) | SMN1; SMN2LMNAHTTALDH1A1MEN1 | |
| SCHEMBL4867430 | 0.79 | LMNA (0.50) | SMN1; SMN2LMNAHTTALDH1A1FUCA1 | |
| SCHEMBL4861409 | 0.79 | CTSL (0.53) | SMN1; SMN2LMNAHTTALDH1A1MEN1 | |
| SCHEMBL3647693 | 0.79 | CTSL (0.53) | SMN1; SMN2LMNAHTTALDH1A1MEN1 | |
| SCHEMBL4866736 | 0.78 | ALDH1A1 (0.46) | SMN1; SMN2LMNAHTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | SMN1; SMN2 2654/4885LMNA 2515/4885HTT 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.